P=N/A, N=248, Not yet recruiting, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Tec

In conclusion, AMPK-mediated PI3K/mTOR, Nrf2, and NF-κB signaling pathways may all be involved in the therapeutic benefits of TRI for CIPN. These results indicate that TRI may be useful for reducing the side effects of CIPN and enhancing patient outcomes during cisplatin chemotherapy.

P2, N=138, Active, not recruiting, Medical University of Graz | Recruiting --> Active, not recruiting

P4, N=175, Completed, Prisma Health-Upstate | N=132 --> 175

P3, N=60, Recruiting, Ain Shams University

Our research has revealed that Dronedarone hydrochloride, an FDA-approved drug, is an SRC inhibitor that can suppress the growth of GC cells by blocking the SRC/AKT1 signaling pathway. It provides a scientific basis for use in the clinical treatment of GC.

Finally, we assessed the anti-cancer effects of DH in a pancreatic cancer mouse model and found that DH treatment suppressed pancreatic tumor development in vivo. Collectively, our investigation demonstrates that DH triggers pyroptosis in PDAC and proposes its potential effects on anti-PDAC growth.

P4, N=0, Withdrawn, Peking University Third Hospital | N=414 --> 0 | Not yet recruiting --> Withdrawn

The use of combination therapies, such as hydroxyurea alongside diltiazem, suggests more efficient and effective MG management compared to monotherapy. Since the efficacy of traditional therapies is limited in most cases due to resistance mechanisms in CSCs, further studies on the biology of CSCs are warranted to develop therapeutic interventions that are likely to be effective in MG. Consequently, improved diagnostic approaches may lead to personalised treatment plans tailored to the specific needs of each patient.

Male Swiss albino mice were injected with LPS (500 µg/kg, i.p) every other day alone or parallel with oral doses of either escitalopram (Esc) (10 mg/kg/day) or TMZ (20 mg/kg/day) for 14 days. Here we showed that TMZ is an affluent nominee for depression management via targeting TLR4/NF-κB and Nrf2/HO-1 pathways. Future research addressing TMZ-antidepressant activity in humans is mandatory to enroll it as a novel therapeutic strategy for depression.

P4, N=2, Enrolling by invitation, Vanderbilt University Medical Center | Initiation date: Aug 2024 --> Nov 2024

P2, N=129, Completed, Bial - Portela C S.A.

P=N/A, N=618, Not yet recruiting, Medical College of Wisconsin | Phase classification: P4 --> P=N/A

P4, N=56, Completed, Guangzhou Panyu Central Hospital; Guangzhou Panyu Central Hospital

P1, N=62, Completed, Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University

The cytometric analysis showed that the tested compounds (especially EDAG-8) are inhibitors of BCRP, MDR1, and MRP1 efflux pumps (more potent than the reference compounds-novobiocin, verapamil, and MK-571). An in silico study correlates with these results, suggesting that the compound with the lowest binding energy to these transporters (EDAG-8) has a more favorable spatial structure affecting its anticancer activity, making it a promising candidate in the development of a novel anticancer agent for future breast cancer therapy.

Furthermore, dronedarone suppressed the growth of ESCC in patient-derived tumor xenograft models in vivo. Thus, our study demonstrated that dronedarone could be repurposed as a CDK4/6 inhibitor for ESCC chemoprevention.

Lacidipine demonstrated a protective effect in UC, reducing inflammation and modulating key signaling pathways. These findings suggest that lacidipine could be a promising candidate for the treatment of UC.

P3, N=582, Completed, Eisai Ltd | Not yet recruiting --> Completed

Based on these novel findings, ESL has the potential for further experimental and clinical studies in glioblastoma.

P=N/A, N=217, Completed, Istanbul Medipol University Hospital | Trial completion date: Jun 2022 --> Aug 2024

We have reported that exo-C3-N-Dbn--Trp2 (13) as a lead ABCB1 inhibitor that is more effective than Verapamil...We correlate that the predictions based on the inhibitor interactions at the access tunnel provide clues about the design of improved ABCB1 inhibitors. This work lays the foundation for the design of a new class of inhibitors from a cyclo-L-Trp-L-Trp DKP scaffold.

P4, N=618, Not yet recruiting, Medical College of Wisconsin | Phase classification: P3 --> P4

P=N/A, N=520, Recruiting, Boston Scientific Corporation | N=387 --> 520

P3, N=180, Recruiting, Rose Research Center, LLC | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Feb 2024 --> Dec 2024

P=N/A, N=126, Not yet recruiting, Western Galilee Hospital-Nahariya

P3, N=500, Active, not recruiting, Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting

P=N/A, N=165, Completed, University of Lausanne Hospitals | Active, not recruiting --> Completed

P4, N=2, Enrolling by invitation, Vanderbilt University Medical Center

P4, N=92, Recruiting, Aurora Health Care | Trial primary completion date: Jun 2024 --> Nov 2024

P2, N=183, Recruiting, American University of Beirut Medical Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025

Zonisamide improved locomotor function and reduced serum TNF-α levels, as well as APAF-1 and TNF-α expression in cerebellar tissues. These findings suggest that zonisamide exerts its protective effects by modulating immune and inflammatory pathways, thereby preserving cerebellar integrity and function.

We further revealed that the combination of TET with αPD-1 monoclonal antibody (αPD-1 mAb) yields significant anti-cancer effects by promoting CD8+ T cell infiltration and enhancing its cell-killing effect, which in turn reduced the growth of tumors and prolonged survival of NSCLC mice. Therefore, TET effectively eliminates NSCLC cells and enhances immunotherapy efficacy through the activation of the STING pathway, and combining TET with anti-PD-1 immunotherapy deserves further exploration for applications.

P4, N=120, Active, not recruiting, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting --> Active, not recruiting | N=180 --> 120

P4, N=150, Not yet recruiting, Third Military Medical University

P=N/A, N=144, Recruiting, Subei people's Hospital; Subei people's Hospital | Not yet recruiting --> Recruiting

By molecular simulations of ABCB1-substrate interactions, we generated a benzylated Cyclo-tryptophan (C3N-Dbn-Trp2) that inhibits ABCB1 activity with efficacy comparable to or better than the classical inhibitor, verapamil. C3N-Dbn-Trp2 restored chemotherapy sensitivity in drug-resistant human cancer cells with no adverse effect on cell proliferation. Our unique approach presents a promising lead toward developing effective ABCB1 inhibitors to treat drug-resistant cancers.

P3, N=1097, Terminated, Milestone Pharmaceuticals Inc. | N=748 --> 1097 | Completed --> Terminated; The closure of the event-driven study was terminated due to the total sample size was reached.

The results of treating subcutaneous xenograft tumors with a combination of tetrandrine and chloroquine validated that autophagy inhibition enhances the toxicity of tetrandrine against pancreatic cancer in vivo. Altogether, our study demonstrates that tetrandrine induces cytoprotective autophagy in pancreatic cancer cells. Inhibiting tetrandrine-induced autophagy promotes the accumulation of ROS and enhances its toxicity against pancreatic cancer.

P1, N=100, Active, not recruiting, Tactical Therapeutics, Inc. | Trial completion date: Jan 2024 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025

P=N/A, N=15, Completed, Queen Mary University of London | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023

P=N/A, N=4000, Active, not recruiting, Daewoong Pharmaceutical Co. LTD. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Nov 2024